A citation-based method for searching scientific literature

L M Knapen, J van Dalem, Y C Keulemans, N P van Erp, M T Bazelier, M L De Bruin, H G M Leufkens, S Croes, C Neef, F de Vries, J H M Driessen. Diabetes Obes Metab 2016
Times Cited: 21







List of co-cited articles
119 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.
Michael Elashoff, Aleksey V Matveyenko, Belinda Gier, Robert Elashoff, Peter C Butler. Gastroenterology 2011
536
57

Pancreatic safety of incretin-based drugs--FDA and EMA assessment.
Amy G Egan, Eberhard Blind, Kristina Dunder, Pieter A de Graeff, B Timothy Hummer, Todd Bourcier, Curtis Rosebraugh. N Engl J Med 2014
316
47

Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study.
Laurent Azoulay, Kristian B Filion, Robert W Platt, Matthew Dahl, Colin R Dormuth, Kristin K Clemens, Madeleine Durand, David N Juurlink, Laura E Targownik, Tanvir C Turin,[...]. BMJ 2016
61
47

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Jennifer B Green, M Angelyn Bethel, Paul W Armstrong, John B Buse, Samuel S Engel, Jyotsna Garg, Robert Josse, Keith D Kaufman, Joerg Koglin, Scott Korn,[...]. N Engl J Med 2015
38

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
38

Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study.
M Gokhale, J B Buse, C L Gray, V Pate, M A Marquis, T Stürmer. Diabetes Obes Metab 2014
52
38

Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
William B White, Christopher P Cannon, Simon R Heller, Steven E Nissen, Richard M Bergenstal, George L Bakris, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer,[...]. N Engl J Med 2013
38


Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies.
Ling Li, Jiantong Shen, Malgorzata M Bala, Jason W Busse, Shanil Ebrahim, Per Olav Vandvik, Lorena P Rios, German Malaga, Evelyn Wong, Zahra Sohani,[...]. BMJ 2014
140
33


Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population.
John A Romley, Dana P Goldman, Matthew Solomon, Daniel McFadden, Anne L Peters. Diabetes Technol Ther 2012
62
28



A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?
Peter C Butler, Michael Elashoff, Robert Elashoff, Edwin A M Gale. Diabetes Care 2013
192
23

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.
Sonal Singh, Hsien-Yen Chang, Thomas M Richards, Jonathan P Weiner, Jeanne M Clark, Jodi B Segal. JAMA Intern Med 2013
255
23

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
23


Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study.
Lotte M Knapen, Roy G P J de Jong, Johanna H M Driessen, Yolande C Keulemans, Nielka P van Erp, Marie L De Bruin, Hubert G M Leufkens, Sander Croes, Frank de Vries. Diabetes Obes Metab 2017
14
35

Data Resource Profile: Clinical Practice Research Datalink (CPRD).
Emily Herrett, Arlene M Gallagher, Krishnan Bhaskaran, Harriet Forbes, Rohini Mathur, Tjeerd van Staa, Liam Smeeth. Int J Epidemiol 2015
19



Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
Marc A Pfeffer, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C Gerstein, Lars V Køber, Francesca C Lawson, Lin Ping, Xiaodan Wei, Eldrin F Lewis,[...]. N Engl J Med 2015
19

Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptin.
Itamar Raz, Deepak L Bhatt, Boaz Hirshberg, Ofri Mosenzon, Benjamin M Scirica, Amarachi Umez-Eronini, KyungAh Im, Christina Stahre, Alona Buskila, Nayyar Iqbal,[...]. Diabetes Care 2014
44
19


Distant metastasis occurs late during the genetic evolution of pancreatic cancer.
Shinichi Yachida, Siân Jones, Ivana Bozic, Tibor Antal, Rebecca Leary, Baojin Fu, Mihoko Kamiyama, Ralph H Hruban, James R Eshleman, Martin A Nowak,[...]. Nature 2010
19


Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis.
Laurent Azoulay, Kristian B Filion, Robert W Platt, Matthew Dahl, Colin R Dormuth, Kristin K Clemens, Madeleine Durand, Nianping Hu, David N Juurlink, J Michael Paterson,[...]. JAMA Intern Med 2016
53
19

Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.
Matteo Monami, Besmir Nreu, Alessia Scatena, Barbara Cresci, Francesco Andreozzi, Giorgio Sesti, Edoardo Mannucci. Diabetes Obes Metab 2017
71
19



Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials.
Matteo Monami, Ilaria Dicembrini, Camilla Nardini, Irene Fiordelli, Edoardo Mannucci. Diabetes Res Clin Pract 2014
55
14

The biology of incretin hormones.
Daniel J Drucker. Cell Metab 2006
14



A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer.
Carlos Alves, Francisco Batel-Marques, Ana F Macedo. Diabetes Res Clin Pract 2012
102
14


Incretin-based therapy and risk of acute pancreatitis: a nationwide population-based case-control study.
Reimar Wernich Thomsen, Lars Pedersen, Niels Møller, Johnny Kahlert, Henning Beck-Nielsen, Henrik Toft Sørensen. Diabetes Care 2015
56
14


Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study.
Jean-Luc Faillie, Laurent Azoulay, Valerie Patenaude, Dominique Hillaire-Buys, Samy Suissa. BMJ 2014
56
14

Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials.
M B Rehman, B V Tudrej, J Soustre, M Buisson, P Archambault, D Pouchain, H Vaillant-Roussel, F Gueyffier, J-L Faillie, M-C Perault-Pochat,[...]. Diabetes Metab 2017
59
14

Incretin-based pharmacotherapy and risk of adverse pancreatic events in the ethnic Chinese with diabetes mellitus: A population-based study in Taiwan.
Chao-Ming Tseng, Wei-Chih Liao, Chi-Yang Chang, Ching-Tai Lee, Cheng-Hao Tseng, Yao-Chun Hsu, Jaw-Town Lin. Pancreatology 2017
9
33

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
14


Dipeptidyl Peptidase-4 Inhibitor Use Is Not Associated With Acute Pancreatitis in High-Risk Type 2 Diabetic Patients: A Nationwide Cohort Study.
Chia-Hsuin Chang, Jou-Wei Lin, Shu-Ting Chen, Mei-Shu Lai, Lee-Ming Chuang, Yi-Cheng Chang. Medicine (Baltimore) 2016
14
21

Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes.
Eleni Bekiari, Chrysoula Rizava, Eleni Athanasiadou, Konstantinos Papatheodorou, Aris Liakos, Thomas Karagiannis, Maria Mainou, Maria Rika, Panagiota Boura, Apostolos Tsapas. Endocrine 2016
32
14

The physiology of glucagon-like peptide 1.
Jens Juul Holst. Physiol Rev 2007
9

New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer.
Rahul Pannala, Ananda Basu, Gloria M Petersen, Suresh T Chari. Lancet Oncol 2009
315
9

Incretin-based therapies in the treatment of type 2 diabetes--more than meets the eye?
Krzysztof Labuzek, Michał Kozłowski, Dawid Szkudłapski, Patrycja Sikorska, Monika Kozłowska, Bogusław Okopień. Eur J Intern Med 2013
29
9

Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials.
Matteo Monami, Ilaria Dicembrini, Daniele Martelli, Edoardo Mannucci. Curr Med Res Opin 2011
155
9

Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis.
Deepson S Shyangdan, Pamela L Royle, Christine Clar, Pawana Sharma, Norman R Waugh. BMC Endocr Disord 2010
61
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.